Identification a novel de novo RUNX2 frameshift mutation associated with cleidocranial dysplasia

Genes Genomics. 2022 Jun;44(6):683-690. doi: 10.1007/s13258-022-01229-w. Epub 2022 Mar 2.

Abstract

Background: Cleidocranial dysplasia (CCD) is a rare genetic disorder affecting bone and cartilage development. Clinical features of CCD comprise short stature, delayed ossification of craniofacial structures with numerous Wormian bones, underdeveloped or aplastic clavicles and multiple dental anomalies. Several studies have revealed that CCD development is strongly linked with different mutations in runt-related transcription factor 2 (RUNX2) gene.

Objective: Identification and functional characterization of RUNX2 mutation associated with CCD.

Methods: We performed genetic testing of a patient with CCD using whole exome sequencing and found a novel RUNX2 frameshift mutation: c.1550delT in a sporadic case. We also compared the functional activity of the mutant and wild-type RUNX2 through immunofluorescence microscopy and osteocalcin promoter luciferase assay.

Results: We found a novel RUNX2 frameshift mutation, c.1550delT (p.Trp518Glyfs*60). Both mutant RUNX2 and wild-type RUNX2 protein were similarly confined in the nuclei. The novel mutation caused abrogative transactivation activity of RUNX2 on osteocalcin promoter.

Conclusions: We explored a novel RUNX2 deletion/frameshift mutation in a sporadic CCD patient. This finding suggests that the VWRPY domain may play a key role in RUNX2 transactivation ability.

Keywords: Cleidocranial dysplasia; Genetic disorder; Novel mutation; RUNX2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cleidocranial Dysplasia* / genetics
  • Core Binding Factor Alpha 1 Subunit* / genetics
  • Frameshift Mutation
  • Humans
  • Mutation
  • Osteocalcin / genetics

Substances

  • Core Binding Factor Alpha 1 Subunit
  • RUNX2 protein, human
  • Osteocalcin